Determinants of mortality in patients with Severe Sepsis

Medical Decision Making

Volumn 25, Issue 4, 2005, Pages 374-386

  Johnston, Joseph A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

APACHE II; Critical illness; Prognostication; Risk assessment; Sepsis; Severity of illness index

Indexed keywords

DROTRECOGIN;

ACCURACY; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; DIAGNOSTIC VALUE; FEMALE; HIGH RISK POPULATION; HUMAN; INFANT; INTENSIVE CARE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEPSIS;

EID: 22544444220     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X05278933     Document Type: Article

References (30)

1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-29.
2. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619-36.
3. Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med. 1995;122:191-203.
4. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-63.
5. Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. JAMA. 1993;270:2478-86.
6. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-17. [Erratum, 1999;340:1056]
7. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-67.
8. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
9. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
10. Siegel JP. Assessing the use of protein C in the treatment of severe sepsis. N Engl J Med. 2002;347:1030-4.
11. Lemeshow S, Klar J, Teres D. Outcome prediction for individual intensive care patients: useful, misused, or abused? Intensive Care Med. 1995;21:770-6.
12. Ridley SA. Uncertainty and scoring systems. Anaesthesia. 2002;57:761-7.
13. Schafer J-H, Maurer A, Jochimsen F, et al. Outcome prediction models on admission in a medical intensive care unit: do they predict individual outcome? Crit Care Med. 1990;18:1111-8.
14. Sherck JP, Shatney CH. ICU scoring systems do not allow prediction of patient outcomes or comparison of ICU performance. Crit Care Clin. 1996;12:515-23.
15. Polderman KH, Christiaans HMT, Wester JP, Spijkstra JJ, Girbes ARJ. Intra-observer variability in APACHE II scoring. Intensive Care Med. 2001;27:1550-2.
16. Wong-Beringer A, Liao C, Nguyen M, Pallares J. Applying patient selection criteria for drotrecogin alfa therapy in practice. Am J Health Syst Pharm. 2003;60:1345-52.
17. Knaus WA, Harrell FE, LaBrecque MS, et al. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. Crit Care Med. 1996;24:46-56.
18. Le Gall JR, Lemeshow S, Leleu G, et al. Customized probability models for early severe sepsis in adult intensive care patients. JAMA. 1995;273:644-50.
19. Knaus WA, Harrell FE, Fisher CJ, et al. The clinical evaluation of new drugs for sepsis. JAMA. 1993;270:1233-41.
20. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. Crit Care Med. 1995;23:376-93.
21. Ely EW, Laterre P-F, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003;31:12-9.
22. Dhainaut J-F, Laterre P-F, LaRosa SP, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med. 2003;31:2291-301.
23. Sollet J-P, Garber GE. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. Am J Surg. 2002;184(Suppl):11S-18S.
24. Localio AR, Berlin JA, Ten Have TR, Kimmel SE. Adjustments for center in multicenter studies: an overview. Ann Intern Med. 2001;135:112-23.
25. Harrell FE Jr. Regression Modeling Strategies. New York: Springer-Verlag; 2001.
26. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. San Francisco: Chapman & Hall; 1993.
27. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-43.
28. Knaus WA, Wagner DP, Zimmerman JE, Draper EA. Variations in mortality and length of stay in intensive care units. Ann Intern Med. 1993;118:753-61.
29. Aird WC. Vascular bed-specific hemostasis: role of endotheliuin in sepsis pathogenesis. Crit Care Med. 2001;29(Suppl):S28-35.
30. Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. Crit Care Med. 2001;29(Suppl):S36-S41.